OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

Core Insights - OptimizeRx Corp. announced organizational updates and leadership advancements aimed at accelerating its Rule of 40 strategy, which focuses on balancing sustained growth with increased profitability [1][2] Leadership Advancements - Ed Stelmakh has been appointed Chief Financial & Strategic Officer (CFSO), expanding his role to include corporate strategy alongside financial leadership, emphasizing profitable growth and shareholder value creation [3] - Theresa Greco continues as Chief Commercial Officer (CCO), overseeing the commercial team and focusing on sustainable revenue growth through a transition to a recurring revenue model [4] - Marion Odence-Ford has been named Chief Legal & Administrative Officer (CLAO), expanding her role to include oversight of key administrative functions and ensuring alignment between legal and strategic initiatives [5] - Doug Besch remains Chief Product & Technology Officer (CPTO), focusing on product enhancements and platform optimization to capture market share in pharma's commercial spend [6] - Brendan Merrell has been appointed Chief Operating Officer (COO), emphasizing operational excellence and driving operating leverage across the company [7] - Andy D'Silva has been promoted to Chief Business Officer (CBO), focusing on strategic planning and championing Rule of 40 strategies to accelerate growth initiatives [8]